

Rachel S. Wightman, MD FACMT FASAM
CURRICULUM VITAE

Associate Professor, Department of Emergency Medicine and Epidemiology
Alpert Medical School of Brown University
Brown Emergency Medicine
55 Claverick Ave
Providence, RI 02903
EMAIL: rachel_wightman@brown.edu

EDUCATION

Undergraduate	Davidson College, Davidson, NC Biology, B.S., 2007
Honors	Davidson Athletic and Academic Scholar Award, NCAA Division I Women's Soccer Athletic and Academic Scholarship, 2003-2007
Medical School	Chicago Medical School, North Chicago, IL M.D., 2011
Honors	<i>Alpha Omega Alpha</i> Honorary Medical Society, 2010 SAEM Award for Excellence in EM, 2011 AMWA Glasgow-Rubin Commendation for Academic Achievement, 2011
Certificates	NYSIM Instructor Simulation Course Certification New York Simulation Center, New York, NY, 2016 EMF/ACEP Emergency Medicine Basic Research Skills Workshop Dallas, TX, 2014-2016

POSTGRADUATE TRAINING

Residency	New York University School of Medicine/ Bellevue Hospital Center, New York, NY Emergency Medicine 2011-2015
Fellowship	New York University School of Medicine/ Bellevue Hospital Center/New York City Poison Control Center New York, NY Medical Toxicology 2015-2017

POSTGRADUATE HONORS AND AWARDS

Michael P. Spadafora Award	American College of Medical Toxicology/MTF 2014
EM Basic Research Skills Scholarship	Emergency Medicine Resident Association 2014
CARE Award	The Miriam Hospital 2019
Leadership Development Seminar for Women Faculty in Medicine and Science	Association of American Medical Colleges 2021
Outstanding Young Investigator	Department of Emergency Medicine, Brown Emergency Medicine 2021
Top Peer Reviewer	Annals of Emergency Medicine 2021
Outstanding Voluntary Service Recognition	American College of Medical Toxicology 2022, 2023
Gregory Jay Research Impact Award	Department of Emergency Medicine, Brown Emergency Medicine 2022
Best Overall Abstract	American Society of Addiction Medicine 54 th Annual Conference, April 14 th 2023
Exemplary Service Award	Department of Emergency Medicine, Brown Emergency Medicine 2023
Outstanding Investigator	Department of Emergency Medicine, Brown Emergency Medicine 2024
Top Peer Reviewer	<i>JAMA</i> 2024

PROFESSIONAL LICENSES, BOARD CERTIFICATIONS, SOCIETY FELLOWSHIP STATUS

New York State Medical License	2015 - 2017
DEA License, Clinical	2015 - Present
Diplomat, Emergency Medicine, American Board of Emergency Medicine	2016 - Present
Rhode Island Medical License	2017 - Present

Diplomat, Medical Toxicology, American Board of Emergency Medicine	2018 - Present
Diplomat, Addiction Medicine, American Board of Preventative Medicine	2021 - Present
Fellow, American College of Medical Toxicology	2022 - Present
Fellow, American Society of Addiction Medicine	2024 - Present
DEA License, Research	2024 - Present

ACADEMIC APPOINTMENTS

Assistant Professor of Emergency Medicine, Department of Emergency Medicine	Division of Medical Toxicology Alpert Medical School of Brown University 2017 - 2023
--	--

Faculty, Addiction Medicine Fellowship Rhode Island Hospital	Department of Internal Medicine, Alpert Medical School of Brown University 2018 - Present
---	---

Assistant Professor of Epidemiology, Department of Epidemiology	Brown School of Public Health 2021 - Present
--	---

Associate Professor of Emergency Medicine, Department of Emergency Medicine	Division of Medical Toxicology Alpert Medical School of Brown University 2023 - Present
--	---

Associate Professor of Epidemiology, Department of Epidemiology	Alpert Medical School of Brown University 2023 - Present
--	---

HOSPITAL APPOINTMENTS

Attending Physician, Department of Emergency Medicine	Brown Emergency Medicine Rhode Island Hospital/The Miriam Hospital 2017 - Present
--	---

STATE APPOINTMENTS

Consultant Medical Director, Substance Use Epidemiology and Drug Overdose Prevention	Rhode Island Department of Health Feb 2023 - Present
--	---

Medical Director	Rhode Island Department of Health CDC Overdose Data2Action Feb 2023 - Present
------------------	---

State Chemical Surge Clinical Advisor	Healthcare Coalition of Rhode Island 2023 – 2024
---------------------------------------	---

OTHER APPOINTMENTS

Consultant, Medical Toxicology	New York City Department of Health & Mental Hygiene CDC OD2A NYC Drug Checking Project
--------------------------------	--

2023 - Present

HOSPITAL COMMITTEES

Pharmacy and Therapeutics Committee

NYU Medical Center
House Staff Member, 2015 - 2017

Medication Safety Committee

NYU Medical Center
House Staff Member, 2015 - 2017

PSI Drug Safety Committee

NYU Medical Center
House Staff Member, 2015 - 2017

Pharmacy and Therapeutics Committee

Lifespan / Brown University Health
Member, 2017 - Present

Director of Toxicology Laboratory
National Search Interviewer

Dept of Pathology and Laboratory Medicine,
Lifespan Health Center, 2019

Medication Safety Committee

Lifespan Hospital Center
Member, 2019 - 2021

Medical Executive Committee

The Miriam Hospital
Member, 2021 – 2022

DEPARTMENTAL COMMITTEES

Toxicology Scholarly Academy

NYU Dept of EM
Member, 2011 - 2017

NYU/Bellevue Women in Emergency Medicine

NYU Dept of EM
Member, 2013 - 2015

Quality, Safety, and Practice Innovation Committee

NYU Dept of EM
House Staff Member, 2014 - 2015

ED Buprenorphine Initiation Advisory Group

Brown Dept of EM
Member, 2019 - 2021

Finance Committee

Brown Dept of EM
Member, 2020 - 2023

Audit Committee

Brown Dept of EM
Member, 2021 - 2022

Compensation Committee

Brown Dept of EM
Member 2022 - Present

UNIVERSITY COMMITTEES

Chicago Medical School Alumni Advisory Committee

Chicago Medical School
Member, 2017 - 2019

Office of Women in Medicine and Science Advisory Board

Alpert Medical School
Member, 2019 - 2023

OTHER COMMITTEES

State

Multidisciplinary Overdose Death Evaluation Committee

RI Department of Health
Member, 2018

Review of Accidental Overdose Deaths Committee

RI Department of Health
Member, 2019 - 2021

Rhode Island Overdose Fatality Review Committee

RI Department of Health
Member, 2021 - Present

RI Governor's Overdose Task Force Treatment Working Group

Member, 2022 - current

National

Buprenorphine Telehealth Consortium

Co-Founder
2020 - 2022

American College of Medical Toxicology
Seminar in Forensic Toxicology

Conference Organizer
2021, 2022, 2023, 2024, 2025

American Board of Emergency Medicine

Oral Board Examiner
2022, 2023

MEMBERSHIP IN SOCIETIES

Alpha Omega Alpha Honor Society

2010 - 2015

American College of Emergency Physicians

2011 - 2015

Emergency Medicine Residents' Association
Awards Selection Committee

2011 - 2017

Member, 2014 - 2015

American Academy of Clinical Toxicology

2015 - Present

American College of Medical Toxicology

2015 - Present

Medication Management Committee

Member, 2017 - 2023

Addiction Medicine Committee

Member, 2018 - 2023

American Society of Addiction Medicine

2021 - Present

Society of Academic Emergency Medicine

2022 - 2024

PUBLICATION LIST

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Mahajan AK, Patel S, Hogarth DK, **Wightman R**. Electromagnetic navigational bronchoscopy: an effective and safe approach to diagnose peripheral lung lesions unreachable by conventional bronchoscopy in high-risk patients. *J Bronchology Interv Pulmonol*. April 2011;18(2):133-7. DOI:10.1097/LBR.0b013e318216cee6.
2. **Wightman R**, Zell-Kanter M, Van Roo J, Leikin J. Zonisamide Toxicity in a Patient with an Intentional Overdose. *Ann Pharmacother*. April 2011;45(4):547. DOI:10.1345/aph.1P597.
3. **Wightman R**, Perrone J, Portelli I, Nelson L. Likeability and Abuse Liability of Commonly Prescribed Opioids. *J Med Toxicol*. December 2012;8(4):335-40. DOI:10.1007/s13181-012-0263-x.
4. **Wightman RS**, Read KB, Hoffman RS. Evidence-based management of caustic exposures in the emergency department. *Emerg Med Pract*. May 2016;18(5):1-20. PMID:27074641.
5. **Wightman RS**, Hoffman RS, Howland MA, Rice B, Biary R, Lugassy D. Not your regular high: cardiac dysrhythmias associated with loperamide abuse. *Clin Tox*. June 2016;54(5):454-8. DOI:10.3109/15563650.2016.1159310.
6. Eggleston W, Marraffa JM, Stork CM, Mercurio-Zappala M, Su MK, **Wightman RS**, Cummings KR, Schier JG. Notes from the field: Cardiac dysrhythmias after loperamide abuse- New York, 2008-2016. *MMWR Morb Mortal Wkly Rep*. November 2016;65(45):1276-1277. DOI:10.15585/mmwr.mm6545a7.
7. Velazquez DM, Markowitz ME, Forman K, **Wightman RS**, Su MK, Nafday S. A neonate with lead toxicity. *Neoreviews*. March 2017;18(3):e180-e183. DOI:10.1542/neo.18-3-e184.
8. **Wightman RS**, Perrone J, Erowid F, Erowid E, Meisel ZF, Nelson LS. Comparative analysis of opioid queries on Erowid.org: An opportunity to advance harm reduction. *Substance Use & Misuse*. April 24, 2017;52(10):1315-1319. DOI:10.1080/10926084.2016.1276600.
9. **Wightman RS**, Nelson LS, Lee JD, Fox LM, Smith SW. Precipitated opioid withdrawal from Vivitrol®. *The American Journal of Emergency*. Jun 2018;36(6):1128.e2. DOI:10.1016/j.ajem.2018.03.052.
10. Ali S, **Wightman RS**, Hack J. Acute Respiratory Failure from Cement Exposure: A Case Report and Review of the Literature. *Rhode Island Medical Journal*. February 2019:55-57. PMID:30709077.

11. Jarman AF, MacLean JV, Barron RJ, **Wightman RS**, McGregor AJ. Brexanolone for post-partum depression: a novel approach and a call for comprehensive post-partum care. *Clin Ther*. January 2020;42(1):231-235. DOI:10.1016/j.clinthera.2019.11.005.
12. Kunzler N, **Wightman RS**, Nelson LS. Opioid withdrawal precipitated by long-acting antagonists. *Journal of Emergency Medicine*. February 2020;58(2):245-253. DOI:10.1016/j.jemergmed.20119.015.
13. Zeyl V, Sawyer K, **Wightman RS**. What do you know about maryjane? A systematic review of the current data on the THC:CBD ratio. *Substance Use & Misuse*. March 2020;55(8):1223-1227. DOI:10.1080/10826084.2020.1731547.
14. Samuels EA, Clark SA, Wunsch C, Jordison Keeler LA, Reddy N, Vanjani R, **Wightman RS**. Innovations during COVID-19: Improving addiction treatment access. *J Addict Med*. Jul/Aug 2020;14(4):e8-e9. DOI:10.1097/ADM.0000000000000685.
15. Meehan C, **Wightman RS**. A Case Report of Isopropanol Ingestion During the SARS-CoV-2 Pandemic. *J Addict Med*. Sept/Oct 2020;14(5):e264-e266. DOI:10.1097/ADM.0000000000000728.
16. **Wightman RS**, Perrone J, Scagos R, Krieger M, Nelson LS, Marshall BDL. Opioid Overdose deaths with buprenorphine detected in postmortem toxicology: a retrospective analysis. *J Med Tox*. January 2021;17(1):10-15. DOI:10.1007/s13181-020-00795-3.
17. Collins A, Beaudoin F, Samuels EA, **Wightman RS**, Baird J. The impact of COVID-19 on service provision for emergency department patients post-opioid overdose: A field report. *J Addict Med*. Sept-Oct 2021;15(5):432-434. DOI:10.1097/ADM.0000000000000779.
18. Clark SA, Davis C, Wunsch C, **Wightman RS**, Jordison Keeler L, Reddy N, Samuels EA. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. *JSAT*. May 2021;124:109293. DOI:10.1016/j.jsat.2021.108283.
19. **Wightman RS**, Erowid E, Erowid F, Thyssen S, Wheeler M, Pulmonskas B, Olson R, Green TC. Confirmed reports of bupropion sold as crack cocaine in the illicit drug supply. *Clin Tox*. November 2021;59(11):1031-1032. DOI:10.1080/155563650.2021.1898632.
20. Collins A, Beaudoin FL, Samuels EA, **Wightman RS**, Baird J. Facilitators and barriers to post-overdose service delivery in Rhode Island emergency departments: Implications for state policy. *JSAT*. November 2021;130:108411. DOI:10.1016/j.sat.2021.108411.
21. **Wightman RS**, Perrone J, Scagos R, Hallowell BD, Krieger M, Li Y, McGregor AJ, Nelson LS, Marshall BDL. Toxicological and pharmacologic sex differences in

unintentional or undetermined opioid overdose death. *Drug Alcohol Depend.* October 2021;227:108994. DOI:10.1016/j.drugalcdep.2021.108994.

22. **Wightman RS**, Jacka B, Uber J, McKenzie M, Reddy NG, Winters R, Jordison Keeler LA, Samuels EA. Tele-buprenorphine for emergency department overdose visit follow up and treatment initiation. *AJEM.* December 2021;50:409-412. DOI:10.1016/j.ajem.2021.08.071.
23. Samuels EA, Khatri UG, Snyder H, **Wightman RS**, Tofighi B, Krawczyk N. Buprenorphine telehealth treatment initiation and follow-up during COVID -19. *Journal of General Internal Medicine.* April 2022;37(5):1331-1333. DOI:10.1007/s11606-021-07249-8.
24. Jacka BP, Ziobrowski HN, Lawrence A, Baird J, Wentz AE, Marshall BDL, **Wightman RS**, Mello MJ, Beaudoin FL, Samuels EA . Implementation and Maintenance of an Emergency Department Naloxone Distribution and Peer Recovery Specialist Program. *Acad Emerg Med.* March 2022;29(3):294-307. DOI:10.1111/acem.14409.
25. Green TC, Olson R, Jarczyk C, Erowid E, Erowid F, Thyssen S, **Wightman RS**, delPozo B, Michelson L, Cormier J, Consigli A, Reilly B, Ruiz S. Implementation and validation of the Massachusetts Drug Supply Data Stream: a state-wide public health-public safety partnership drug checking program. *J Public Health Manag Pract.* Nov-Dec 2022; 28 (suppl 6):S347-S354. DOI:10.1097/PHH.0000000000001581.
26. Volpe K, **Wightman RS**. Delta what? Deciphering the world of cannabinoids. *Rhode Island Medical Journal.* September 2022;105(7):37-41. PMID:36041020.
27. Weidele HR, **Wightman R**, St John K, Marchetti L, Bratberg J, Hallowell BD. Fentanyl and fentanyl analogs detected among unintentional opioid involved overdose deaths in Rhode Island: January 2019- December 2021. *Rhode Island Medical Journal.* December 2022;105(10):64-66. PMID:36413456.
28. Wunsch C, **Wightman RS**, Pratty C, Jacka B, Hallowell BD, Clark S, Davis C, Samuels EA. Thirty-day treatment continuation after audio-only buprenorphine telehealth initiation. *Journal of Addiction Medicine.* Mar-Apr 2023;17(2):206-209. DOI:10.1097/ADM.0000000000001077.
29. Del Pozo B, Atkins D, Adraka-Crisou B, **Wightman RS**, Clark MH, Huynh P, Ray B. Buprenorphine involvement in opioid overdose deaths: a retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021. *Drug and Alcohol Dependence Reports.* March 2023;6:100131.DOI:10.1016/j.dadr.2023.100131.
30. Stewart K, Francis V, **Wightman RS**. Statewide variation in cannabinoid regulations. *Rhode Island Medical Journal.* March 2023;106(2):31-33. PMID:3684540.

31. **Wightman RS**, Perrone J, Collins AB, Lakamana S, Sarker A. An Analysis of Cannabinoid Hyperemesis Syndrome Reddit Posts and Themes. *Clin Tox.* April 2023;62(4):283-289. DOI:10.1080/15563650.2023.2183790.
32. Collins AB, Beaudoin FL, Metrik J, **Wightman RS**. “I still partly think this is bullshit”: A qualitative analysis of cannabinoid hyperemesis syndrome perceptions among people with chronic cannabis use and cyclic vomiting. *Drug and Alcohol Dependence.* May 2023;246:109853. DOI:10.1016/j.drugalcdep.2023.109853.
33. Paiva TJ, St. John K, **Wightman RS**, Nitenson AZ, Onyejekwe C, Hallowell BD. Increased stimulant prescribing following COVID-19 pandemic- Rhode Island 2017-2021. *Rhode Island Medical Journal.* July 2023;106(6):50-53. PMID:37368836.
34. **Wightman RS**, Metrik J, Lin TR, Li Y, Badea A, Almerida R, Collins AB, Beaudoin FL. Cannabis use patterns and whole blood cannabinoid profiles of emergency department patients with suspected cannabinoid hyperemesis syndrome. *Annals of Emergency Medicine.* August 2023;82(2):121-130. DOI:10.1016/j.annemergmed.2023.03.005.
35. Collins AB, **Wightman RS**, Macon C, Shihpar A, Krieger M, Elmaleh R, Smith MC, Morales L, Badea A. Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island. *International Journal of Drug Policy.* August 2023;118:104118. DOI:10.1016/j.drugpo.2023.104118.
36. Chambers LC*, Hallowell BD*, Zullo AR, Paiva TJ, Berk J, Gaither R, Hampson AJ, Beaudoin FL, **Wightman RS**. Evaluation of buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. *JAMA Network Open.* September 2023;6(9):e2334540. DOI:10.1001/jamanetworkopen.2023.34540.
37. D’Orazio J, Nelson LS, Perrone J, **Wightman RS**, Haroz R. Xylazine adulteration of the Heroin-Fentanyl drug supply: A narrative review. *Annals of Internal Medicine.* October 2023;176(10):1370-1376. DOI:10.7326/M23-200.1
38. Musisca NJ, Rybasack-Smith H, Mustis A, Petrone G, **Wightman RS**, Smith JL, Brown LL, Fogle JL. Multiple hospital in-situ mass casualty incident training simulation for emergency medicine residents: A sarin bomb scenario. *Rhode Island Medical Journal.* October 2023;106(9):36-40. PMID:37768161.
39. Spadaro A, OConnor K, Lakamana S, Sarkar A, **Wightman RS**, Love J, Perrone J. Self-reported xylazine experiences: a mixed methods study of Reddit subscribers. *Journal of Addiction Medicine.* November/December 2023;17(6):691-694. DOI:10.1097/ADM.0000000000001216.
40. Tofighi B, Lopez R, Araujo G, Lee JD, Samules EA, **Wightman RS**, Butner J. Provider and administrator attitudes and experiences with implementing telebuprenorphine during

the COVID-19 pandemic: a mixed-method survey. *Journal of Substance Use*. January 2024;29(3):347-353. DOI:10.1080/14659891.2023.2166609.

41. Savarino JR, Mokszycki R, Tubbs R, **Wightman RS**. Refractory hypoglycemia due to sulfonylurea contamination of illicit opioid medications. *Rhode Island Medical Journal*. May 2024;107(5):11-13. PMID:38687261.
42. Collins AB, Macon C, Levin S, Wunsch C, **Wightman RS**. “It gets you high as a kite but not unsick”: characterization of and responses to a changing local drug supply by people who use drugs in Rhode Island. *International Journal of Drug Policy*. May 2024;127(104391). DOI:10.1016/j.drugpo.2024.104391.
43. **Wightman RS**, Metrik J, Lin TR, Collins AB, Beaudoin FL. Cannabinoid hyperemesis syndrome: clinical trajectories and patterns of use three months following a visit to the emergency department. *Academic Emergency Medicine*. May 2024;31(5):463-470. DOI:10.1111/acem.14773.
44. Perrone JM, Nelson LS, D’Orazio J, **Wightman RS**, Thakar A, Huntley K, Haroz R. National institute on drug abuse clinical trials network meeting report: managing patients taking xylazine-adulterated opioids in emergency, hospital, and addiction care settings (FKA-2023-1493). *Annals of Emergency Medicine*. July 2024;84(1):20-28. DOI:10.1016/j.annemergmed.2024.01.041.
45. Paiva TJ, **Wightman RS**, St. John K, Nitenson AZ, Onyejekwe C, Hallowell BD. Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency. *Journal of Substance Use and Addiction Research*. July 2024;162:209382. DOI:10.1016/j.j0sat.2024.20982.
46. **Wightman RS**, Chadronet T, Volpe B, Hallowell BD, Nolan LA, Gallagher GB. Substances in counterfeit prescription pills seized by law enforcement in Rhode Island, 2017-2022. *JAMA*. June 2024;331(21):1860-1862. DOI:10.1001/jama.2024.6161.
47. Pappalardo FS, Krieger M, Park C, Beaudoin FL, **Wightman RS**. Patients presenting to the ED with nonfatal drug overdose: self-reported history of overdose and naloxone use. *American Journal of Emergency Medicine*. August 2024;82:21-25. DOI:10.1016/j.ajem.2024.05.007.
48. Yangchen T, Rodriguez M, Baird J, Hallowell BD, Berk J, Gaither R, **Wightman RS**, Beaudoin FL, Chambers L. Trends in recurrent overdose and treatment initiation following emergency department visits for opioid overdose between 2016 and 2021. *Drug and Alcohol Dependence*. September 2024;1(262):111379. DOI:10.1016/j.drugalcdep.2024.111379.
49. Paiva TJ, Hallowell BD, Fischer S, Bratberg J, St John K, Nitenson AZ, **Wightman RS**. Statewide Ketamine and Esketamine Prescribing Trends in Rhode Island, 2017-2023. *Rhode Island Medical Journal*. October 2024;107(10):26-32. PMID:39331010.

50. Armeni K, Chamber L, Peachey A, Berk J, Langdon KJ, Peterson L, Beaudoin FL, **Wightman RS**. Randomized clinical trial of a 16 mg vs 24 mg maintenance daily dose of buprenorphine to increase retention in treatment among people with an opioid use disorder in Rhode Island: study protocol paper. *BMJ Open*. Nov 2024;14:e085888. DOI:10.1136/bmjopen-2024-085888.
51. Das S, Ge Y, Guo Y, Rajwal S, Hairston J, Powell J, Walker D, Peddireddy S, Lakamana S, Bozkurt S, Reyna M, Sameni R, Xiao Y, Kim S, Chandler R, Hernandez N, Mowery D, **Wightman R**, Love J, Spadaro A, Perrone J, Sarker A. Two-layer retrieval augmented generation framework for low-resource medical question-answering using Reddit data: Proof of concept. *J Med Internet Res*. Jan 2025. 6;27:e66220. DOI:10.2196/66220.
52. **Wightman RS**, Hu D. A Case of 7-OH mitragynine use requiring inpatient medically managed withdrawal. *Journal of Addiction Medicine*. August 2025. Online ahead of print. DOI:10.1097/ADM.0000000000001558.
53. Dunham K, Macon C, Joseph R, **Wightman RS**, Collins A. “I wanna know what I’m putting in my body”: Perceptions of drug checking services and supply information among people who use drugs in Rhode Island. *Drug and Alcohol Review*. August 2025. Online ahead of print. DOI: 10.1111/dar.70026.
54. Spadaro A, Hairston J, Lakamana S, **Wightman RS**, Love JS, Perrone J, Sarker A. A Qualitative Analysis and Characterization of Reddit Posts about Xylazine-Associated Wounds. *JMIR Dermatology*. Accepted, pending publication.
55. Bloom J, Beaudoin FL, Lin TR, Gaipo A, Ortega C, **Wightman RS**. Cannabis Use Patterns and Blood Profiles in Pediatric Cannabinoid Hyperemesis Syndrome. *Pediatric Emergency Care*. Accepted, pending publication.

OTHER PEER-REVIEWED PUBLICATIONS:

1. **Wightman R**, Howland MA, Nelson L. Letter to the Editor: a missed opportunity for opioid harm reduction. *Acad Emerg Med*. January 2016;23(1):106. PMID:26670717.
2. **Wightman RS**, Nelson LS. Opioid prescribing: how well do we know ourselves? *J Med Tox*. September 2016;12(3):221-223. DOI:10.1007/s13181-016-0576-2.
3. Croll LS, **Wightman RS**, Hoffman RS. In Response to: “Single versus multiple hyperbaric sessions for carbon monoxide poisoning in a murine model.” *J Med Tox*. October 2016; Epub ahead of print. PMID:27704287.
4. **Wightman RS**, Nelson LS. Letter: Has the die been cast? Discharge of body stuffers from the emergency department. *Eur J Emerg Med*. February 2017;24(1):76. PMID:2798370.

5. Sean R, **Wightman RS**. Cannabinoid Hyperemesis Syndrome. Systematically Testing the Evidence on Marijuana (STEM). Collaborative project between the US Department of Veterans Affairs and the Center for Evidence-based Policy at Oregon Health & Science University. February 2023. <https://www.cannabisevidence.org/clinician-resources/clinician-briefs/cannabinoid-hyperemesis-syndrome/>
6. **Wightman RS**, Nelson LS. Naloxone Dosing in the Era of Fentanyl: The Path Widens by Traveling Down It. *Ann Emerg Med*. August 8, 2022;80(2):127-129. DOI:10.1016/j.annemergmed.2022.04.014.

BOOKS AND BOOK CHAPTERS

1. **Wightman R**, Swaminathan A. (January 2014). Acetaminophen Overdose. In: Greenwood JC, ed. PressorDex 2nd Edition. Irving, Texas: Emergency Medicine Residents' Association: 80-82.
2. **Wightman R**, Biary R. (October 2017). Acetaminophen Overdose. In: Greenwood JC, ed. PressorDex 3rd Edition. Irving, Texas: Emergency Medicine Residents' Association: 72-73.
3. **Wightman R**, Perrone J. (October 2017). Opioids. In Strayer R, Motov S, Nelson L (Eds.), Management of Pain and Procedural Sedation in Acute Care. <http://painandpsa.org/opioids/>.
4. **Wightman RS**, Fulton J. (March 2019). Chapter 103: Caustics. In Nelson LS et al. (Ed.) Goldfrank's Toxicologic Emergencies, 11th Ed. New York, NY: McGraw Hill.
5. **Wightman RS**, Hessler B. (March 2019). Chapter 16: Hemodynamic Principles. In Nelson LS et al. (Ed.) Goldfrank's Toxicologic Emergencies, 11th Ed. New York, NY: McGraw Hill.
6. **Wightman RS**, Nelson LS. (October 2019). Chapter 190: Acetaminophen Toxicity. In Tintinalli JE et al. (Ed.) Tintinalli's Emergency Medicine, 9th Ed. New York, NY: McGraw Hill.
7. **Wightman RS**, Perrone J. (October 2019). Chapter 187: Cocaine/Amphetamine Toxicity. In Tintinalli JE et al. (Ed.) Tintinalli's Emergency Medicine, 9th Ed. New York, NY: McGraw Hill.
8. Hase T, **Wightman R** (June 2020). Acetaminophen Overdose. In: Greenwood JC, ed. PressorDex: Critical Care Medications Guide. 4th Edition. Irving, Texas: Emergency Medicine Residents' Association: 78-79.
9. Bloom J, **Wightman RS** (2024). Acetaminophen Overdose. In: Greenwood JC, ed. PressorDex: Critical Care Medications Guide. 5th Edition. Irving, Texas: Emergency Medicine Residents' Association: 83-84.

OTHER MEDIA

Selected Broadcast Media Highlights, Interviews, Editorials, and Public Health Alerts

1. “Health check: the truth about synthetic cannabinoids.” NBC10 WJAR. Interview with Barbara Morse Silva. August 16, 2018. <https://turnto10.com/features/health-landing-page/health-check-dangers-of-synthetic-marijuana>.
2. “In COVID-19’s shadow, R.I. overdose deaths spiral. This 24/7 hotline gets around barriers to offer warmth, relief, treatment.” Providence Journal. July 3 2020. <https://www.providencejournal.com/news/20200703/in-covid-19s-shadow-ri-overdose-deaths-spiral-this-247-hotline-gets-around-barriers-to-offer-warmth-relief-treatment>.
3. “Fentanyl Safety Roll Call Video.” Content Expert. Massachusetts Police Assisted Addiction and Recovery Initiative (PAARI). May 2020. <https://paarius.org/rolldocuments/>.
4. Manz J, Antezzo M, Mette E, Purlington K. “State Strategies to Support OUD Treatment Across the Criminal Legal System.” National Academy for State Health Policy. Highlight RI Buprenorphine Hotline as an opportunity to prevent a crisis event. Provided content expertise related to RI Buprenorphine Hotline. <https://www.nashp.org/opioid-center/treatment-in-the-legal-system/#toggle-id-2>. March 2021.
5. “Brown initiative tracks risks in local drug supply, public warned of potential harm.” Jacquelyn Voghel. Providence Business News. June 9, 2022. <https://pbn.com/brown-initiative-tracks-risks-in-local-drug-supply-public-warned-of-potential-harm/>.
6. “Brown researchers aim to save lives by testing illicit drugs for secret, often deadly ingredients.” Abdullah Shihpar. News from Brown. July 27, 2022. <https://www.brown.edu/news/2022-07-27/testri>.
7. “Cannabis hyperemesis and the cure that burns.” Laurel Oldach. ASBMB Today. August 3, 2022. <https://www.asbmb.org/asbmb-today/science/080322/the-cure-that-burns>.
8. “Study: RI’s illicit drug supply constantly changing.” Sarah Doiron. WPRI.com. December 15, 2022. <https://www.wpri.com/health/study-ri-illicit-drug-supply-is-constantly-changing/>.
9. “An animal tranquilizer is showing up in the nation’s illicit drug supply.” Nicole Wetsman. ABCNews. December 22, 2022. <https://abcnews.go.com/Health/animal-tranquilizer-showing-nations-illicit-drug-supply/story?id=95661520>.
10. “What to know about Tranq, the animal sedative infiltrating street drugs.” Sarah Kuta. Smithsonian Magazine. January 9, 2023. <https://www.smithsonianmag.com/smart->

[news/what-to-know-about-tranq-the-animal-sedative-infiltrating-street-drugs-180981408/](#).

11. “Enormous problems: animal sedative found in local drug supply increases overdose risk.” Jack Perry. The Providence Journal. January 20, 2023. [https://www.providencejournal.com/story/news/drugs/2023/01/20/animal-sedative-xylazine-ri-drug-supply-increases-overdose-risk/69821190007/](#).
12. “Building comprehensive responses to the opioids crisis.” Transforming Care. January 31, 2023. The Commonwealth Fund. [https://www.commonwealthfund.org/publications/2023/jan/building-comprehensive-responses-opioid-crisis?utm_source=alert&utm_medium=email&utm_campaign=Improving+Health+Care+Quality](#).
13. “Study of R.I. drug supply shows prevalence of animal tranquilizer: Brown’s testRI warns about effects of xylazine, spreads awareness.” The Brown Daily Herald. January 26, 2023. [https://www.browndailyherald.com/article/2023/01/study-of-r-i-drug-supply-shows-prevalence-of-animal-tranquilizer](#).
14. “People are going to start losing limbs: Animal ‘tranq’ is reshaping RI’s drug landscape.” Providence Journal. February 15, 2023. [https://www.providencejournal.com/story/news/crime/2023/02/15/xylazine-aka-tranq-making-big-impact-in-ri-drug-landscape-narcan/69865850007/](#).
15. “Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder.” News from Brown. September 18, 2023. [https://www.brown.edu/news/2023-09-18/buprenorphine-dose](#).
16. “In the era of fentanyl, treating opioid addiction may mean a higher dose.” Lynn Arditi. The Public’s Radio (NPR Rhode Island). September 18, 2023. [https://thepublicsradio.org/article/in-the-era-of-fentanyl-treating-opioid-addiction-may-mean-a-higher-dose-](#).
17. “Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder.” News Release. National Institute on Drug Abuse. September 18, 2023. [https://nida.nih.gov/news-events/news-releases/2023/09/higher-buprenorphine-doses-associated-with-improved-retention-in-treatment-for-opioid-use-disorder](#).
18. “Higher buprenorphine doses associated with improved retention in treatment for opioid use disorder.” Science Magazine. September 18, 2023. [https://scienmag.com/higher-buprenorphine-doses-associated-with-improved-retention-in-treatment-for-opioid-use-disorder/](#).

19. “Fentanyl crisis demands a dose of reality: more buprenorphine?” SciTechDaily. September 20, 2023. <https://scitechdaily.com/fentanyl-crisis-demands-a-dose-of-reality-more-buprenorphine/>.
20. “Higher buprenorphine dose increases likelihood of staying in treatment.” Drugs.com. September 21, 2023. <https://www.drugs.com/news/higher-buprenorphine-increases-likelihood-staying-115113.html>.
21. “Trial Design, treatment options spotlighted in xylazine conference- clinical trials need to include more active users, researcher says.” MedPage Today. October 6, 2023. <https://www.medpagetoday.com/psychiatry/addictions/106682>.
22. “Optimizing dosing of medications for OUD in the era of fentanyl- transforming data into action is the next step.” Wightman RS, Beaudoin FL, Chambers CC. October 22, 2023. <https://www.medpagetoday.com/opinion/second-opinions/106928>.
23. “Xylazine-laced fentanyl overdose: ‘make sure they’re breathing.’” MedPage Today. February 29, 2023. <https://www.medpagetoday.com/publichealthpolicy/publichealth/108970>
24. “Almost all counterfeit oxycontin pills contain fentanyl.” HealthDay. US News and World Report. May 7, 2024. <https://www.usnews.com/news/health-news/articles/2024-05-07/almost-all-counterfeit-oxycontin-pills-contain-fentanyl>.
25. “Study provides comprehensive analysis of Rhode Island’s unregulated drug supply.” Corrie Pikul. News from Brown. May 6, 2024. <https://www.brown.edu/news/2024-05-06/counterfeit-drugs>.
26. “RI’s illicit drug supply is almost all contaminated with fentanyl. Here’s what a study found.” Katie Mulvaney. The Providence Journal. May 28, 2024. <https://www.providencejournal.com/story/news/drugs/2024/05/28/ri-illegal-drug-supply-contains-huge-amounts-of-fentanyl-brown-study/73838031007/>.
27. “Why overdose deaths are falling in Rhode Island, an artist carves crimshaw into plastic trash from the sea, and more.” Luis Hernandez. The Weekly Catch. The Public’s Radio. Interview guest. July 12, 2024. <https://thepublicsradio.org/the-weekly-catch/addiction-experts-on-why-overdose-deaths-are-falling-how-one-artist-carves-scrimshaw-on-plastic-trash-pulled-from-the-sea-and-more/>.
28. “Rhode Island’s Opioid Strategy, PH Detectives Hunt for TB Meds.” Public Health Review Morning Edition. Featured Guest. ASTHO: Association of State and Territorial Health Officials. September 3, 2024. <https://newscast.astho.org/741-rhode-islands-opioid-strategy-ph-detectives-hunt-for-tb-meds/>.

29. “Novel synthetic opioids in the drug supply.” Interview with Sophia Szabo, WPRI. April 17, 2025. <https://www.wpri.com/health/novel-synthetic-opioids-detected-in-ris-illicit-drug-supply/>.
30. “Disorders, syndromes, and even psychosis – the downside to cannabis use.” Podcast interview. Public Health Out Loud, Rhode Island Department of Health. June 12, 2025. <https://podcasts.apple.com/us/podcast/disorders-syndromes-and-even-psychosis-the-downside/id1541663781?i=1000712684767>.
31. “Were on the edge of a crisis”:K2 inside ACI prompts major mail crackdown. July 16, 2025. <https://turnto10.com/news/local/were-on-the-edge-of-a-crisis-k2-inside-aci-prompts-major-mail-crackdown-rhode-island-adult-correctional-institution-july-16-2025>.

ABSTRACTS (National or International)

1. Patel S, Mahajan A, **Wightman R**, Hogarth D.K. Safety and Efficacy of Transbronchial Biopsy without Fluoroscopic Guidance. *Am J Respir Crit Care Med*. April 2009 179(1):A5768. American Thoracic Society International Conference. San Diego, California, May 2009.
2. Mandich N, Szpindor-Watson M, **Wightman R**, Hogarth DK. Diagnostic Utility of Bronchoalveolar Lavage (BAL) in Neutropenic Patients on Antimicrobials. *Am J Respir Crit Care Med*. 2010;181(1):A5154. American Thoracic Society International Conference. New Orleans, Louisiana, May 2010.
3. Szpindor-Watson M, Mandich N, **Wightman R**, Hogarth DK. Higher Levels of Conscious Sedation: A Safe and Effective Tool to Aid the Bronchoscopist. *Am J Respir Crit Care Med*. 2010;181(1):A1604. American Thoracic Society International Conference. New Orleans, Louisiana, May 2010.
4. **Wightman R**, Perrone J, Portelli I, Nelson L. The Liability of Opioid Likability. *Clin Tox*. 2012;A273. Annual Meeting of the North American Congress of Clinical Toxicology. Las Vegas, Nevada, October 2012.
5. Nguyen V, Kramer S, **Wightman RS**, Nelson LS, Hoffman RS. Laundry detergent pod causing esophageal and gastric injury in an adult. *Clin Tox*. 2014;52:A427. European Association of Poison Centers and Clinical Toxicologists Annual Congress. Brussels, Belgium, May 2014.
6. **Wightman RS**, Erowid F, Erowid E, Perrone J, Meisel ZF, Nelson LS. Comparative analysis of trends in opioid queries on Erowid.org 2009-2015. *J Med Toxicol*. 2016;12:A11. American College of Medical Toxicology Annual Scientific Meeting. Huntington Beach, California, March 2016.
7. **Wightman RS**, Perrone J, Erowid F, Erowid E, Meisel ZF, Nelson LS. Relative frequency of unique opioid page visits versus heroin on Erowid.org. *J Med Toxicol*.

2016;12:A12. American College of Medical Toxicology Annual Scientific Meeting. Huntington Beach, California. March 2016.

8. **Wightman RS**, Hoffman RS, Howland MA, Lugassy DM, Biary R. Not your regular high: potentially lethal cardiac dysrhythmias caused by loperamide. *Clin Tox*. 2016;54:A62. European Association of Poison Centres and Clinical Toxicologists Annual Congress. Madrid, Spain, May 2016.
9. **Wightman RS**, Kunzler N, Nelson LS. Precipitated opioid withdrawal from naltrexone injection. *Clin Tox*. 2016;54:A132. European Association of Poison Centres and Clinical Toxicologists Annual Congress. Madrid, Spain, May 2016.
10. Riggan MAA, Chen C, **Wightman RS**, Howland MA, Nelson LS, Hoffman RS, Su M. Fatality following cantharidin ingestion as treatment for gastric cancer. *Clin Tox*. 2016;54(8):668. North American Congress of Clinical Toxicology. Boston, Massachusetts, September 2016.
11. **Wightman RS**, Smith S, Lugassy D. Pediatric single methotrexate pill ingestion: no assessment = no risk? *Clin Tox*. 2016;54(8):756. North American Congress of Clinical Toxicology. Boston, Massachusetts, September 2016.
12. **Wightman RS**, Su MK, Henretig FM, Marcus SM, Velazquez D, Nafday S, Markowitz M. Neonatal lead poisoning treated with chelation. *Clin Tox*. 2016;54(8):679. North American Congress of Clinical Toxicology. Boston, Massachusetts, September 2016.
13. Mudan A, **Wightman RS**, Jang D, Nelson L, Perrone J. A review of cyanide poisoning deaths in the fatality reviews of the NPDS Annual Report 2006-2015. *J Med Tox*. 2018;14(1):49. American College of Medical Toxicology Annual Scientific Meeting. Washington DC, April 2018.
14. Fletcher JM, Hack JB, **Wightman RS**. Digoxin recrudescence: a life-threatening reality for end stage renal disease patients. *J Med Tox*. 2018;14(1):33. American College of Medical Toxicology Annual Scientific Meeting. Washington DC, April 2018.
15. **Wightman RS**, Stehr C. Can the FDA's Adverse Event Reporting System (FAERS) Data Be Used to Assess the Impact of Interventions Such As Risk Evaluation and Mitigation Strategies (REMS)? *Clin Tox*. 2019;57(10):931. North American Congress of Clinical Toxicology Nashville, TN, Sept 2019.
16. Zeyl V, **Wightman RS**. What do you know about Mary Jane? A systematic review of the current data on the THC:CBD ratio. *J Med Tox*. 2020;16:116-168. American College of Medical Toxicology Annual Scientific Meeting, New York, March 2020.
17. **Wightman RS**, Perrone J, Scagos R, Krieger M, Nelson LS, Marshall BDL. Opioid Overdose Deaths With Buprenorphine Detected in Postmortem Toxicology: A

Retrospective Analysis. *J Med Tox.* 2020;16:116-168. American College of Medical Toxicology Annual Scientific Meeting, New York, March 2020.

18. **Wightman RS**, McKenzie M, Jordison Keeler LA, Uber J, Reddy N, Poplaski L, Samuels EA. Linkage to Treatment and Tele-Buprenorphine Post-Emergency Department (ED) Opioid Overdose. 2020 Symposium on Substance Use Research, Virtual Conference, November 2020.
19. **Wightman RS**, Lynch M, Zerbo E, Snyder H, Berk J, Taylor J, Samuels EA. Lessons learned from buprenorphine telehealth during COVID-19: a guide for providers. Blended Educational Session. American Society of Addiction Medicine (ASAM) Virtual 2021. April 23, 2021.
20. Schwarz E, Nelson L, Laes J, Wiegand TJ, **Wightman RS**, Steck A, Haroz R. Excited delirium: the controversy in the care of the acutely agitated patient. Focus Educational Session. American Society of Addiction Medicine (ASAM) Virtual 2021. April 2021.
21. Laes J, **Wightman RS**, Haroz R, Schwarz E, Wiegand TJ, Nelson L. Precipitated Withdrawal: when, where and what to do next. Focus Educational Section. American Society of Addiction Medicine (ASAM) Virtual 2021. April 2021.
22. Haroz R, Laes J, Wiegand TJ, Schwarz E, Steck A, **Wightman RS**, Cienki J, Nelson L. Tricks of the trade- complex buprenorphine inductions. Workshop. American Society of Addiction Medicine (ASAM) Virtual 2021. April 2021.
23. **Wightman RS**, Wunsch C, Clark S, Berk J, Berkowitz L, Jordison Keeler LA, Samuels EA. Low-threshold 24/7 buprenorphine telehealth treatment: innovation to improve access during COVID-19. *J Med Tox.* 2021;17:107. 2021 American College of Medical Toxicology Annual Scientific Meeting. April 2021.
24. Samuels EA, McKenzie M, Jordison Keeler LA, Uber J, **Wightman RS**. Linkage to treatment and tele-buprenorphine post-emergency department (ED) opioid overdose. *J Med Tox.* 2021;17:97. 2021 American College of Medical Toxicology Annual Scientific Meeting. April 2021.
25. **Wightman RS**, Perrone J, Scagos R, Hallowell BD, Krieger M, Li Y, McGregor AJ, Marshall BDL. Toxicological and pharmacologic sex differences in unintentional or undetermined opioid overdose death. *Clin Tox.* 2021;59(11). North American Congress of Clinical Toxicology. Atlanta, GA, Oct 2021.
26. Wunsch C, Lum L, **Wightman RS**, Pratty C, Jacka B, Hallowell B, Clark S, Samuels EA. On demand, audio-only buprenorphine initiation during Covid-19. *Journal of Addiction Medicine.* September/October 2022; 16(5). American Society of Addiction Medicine (ASAM) 53rd Annual Conference, Hollywood, FL, April 2022.

27. Spadaro A, Sarker A, **Wightman RS**, Perrone J: Self reported xylazine exposure and experiences: A mixed methods study of Reddit users. AMERSA Conference. Boston, MA, November 2022
28. Spadaro A, Perrone J, Lakamana S, O'Connor K, **Wightman RS**, Love J, Sarker A. Self-reported xylazine exposure and experiences: a mixed methods study of Reddit users. *Clin Tox.* May 2023;51(1). EAPCCT 2023. Mallorca, Spain, May 2023.
29. **Wightman RS**, Beaudoin FL, Krieger M, Gaipo A, Kaplan S, Tokarz S, Marshall BDL, Badea A. Drug Overdose Testing (DOT) preliminary service data acceptability and feasibility. *J Med Tox.* March 2023;19(2):A144. American College of Medical Toxicology Annual Scientific Meeting 2023. San Diego, CA, April 2023.
30. Collins AB, Badea A, Macon C, Elmaleh R, Joseph R, Krieger M, Shihpar A, **Wightman RS**. testRI: Xylazine detection rates in local drug supply testing. *J Med Tox.* March 2023;19(2):A125. American College of Medical Toxicology Annual Scientific Meeting 2023. San Diego, CA, April 2023.
31. **Wightman RS**, Perrone J, Collins AB, Lakamana S, Sarker A. An analysis of triggers and therapies described in reddit posts of cannabinoid hyperemesis syndrome. *J Med Tox.* March 2023;19(2):A126. American College of Medical Toxicology Annual Scientific Meeting 2023. San Diego, CA, March 2023.
32. **Wightman RS**, Macon C, Badea A, Edwards S, Morales A, Krieger M, A Shihpar, AB Collins. testRI: Communicating changes in the Rhode Island local drug supply. *Journal of Addiction Medicine.* September/October 2023; 17(5). ASAM Annual Conference 2023. April 2023. Washington DC 2023.
33. Gleason L, Barber C, Saia K, Field T, **Wightman RS**, Holland E. Interpreting pregnancy and post-pregnancy fentanyl fat sequestration in urine drug test results. *Journal of Addiction Medicine.* September/October 2023; 17(5). ASAM Annual Conference 2023. April 2023. Washington DC, 2023.
34. **Wightman RS**, Metrik J, Lin T, Li Yu, Badea A, Collins A, Beaudoin F. A prospective investigation of emergency department patients with suspected cannabinoid hyperemesis syndrome. College on Problems of Drug Dependence 85th Annual Scientific Meeting. June 2023. Denver, CO, 2023.
35. Pappalardo F, Krieger M, Park C, Beaudoin F, **Wightman RS**. Naloxone practices and overdose history among patients presenting to the emergency department with non-fatal drug overdose. *Clin Tox.* 2023. 61(2):A101. North American Congress of Clinical Toxicology (NACCT). Montreal, Canada, September 2023.
36. Savarino J, Mokszycki R, Tubbs R, **Wightman RS**. Refractory hypoglycemia due to sulfonylurea contamination of illicit opioid medication. *Clinical Toxicology.* 2023.

61:A351. North American Congress of Clinical Toxicology (NACCT). Montreal, Canada, September 2023.

37. **Wightman RS**, Metrik J, Lin T, Collins A, Beaudoin F. Cannabinoid hyperemesis syndrome: clinical trajectories and patterns of use two weeks following a visit to the emergency department for cyclic vomiting. *Clinical Toxicology*. 2023.61(2):A68. North American Congress of Clinical Toxicology (NACCT). Montreal, Canada, September 2023.
38. Chambers LC, Hallowell BD, Zullo AR, Rodriguez M, Khan MA, Berk J, Gaither R, Beaudoin FL, **Wightman RS**. Risk of Overdose While Engaged in Buprenorphine Treatment for Opioid Use Disorder in the Fentanyl Era. RxSummit. Atlanta, GA, April 2024.
39. Kapadia S, **Wightman RS**, Beaudoin FL, Park C, Krieger MS, Tokarz S, Badea A. Which should you order? Blood vs. urine toxicology LC-QTOF-MS testing. *Journal of Addiction Medicine*. September/October 2025. 18(5). American Society of Addiction Medicine Annual Conference 2024. Dallas, TX, April 2024.
40. Counts C, Sahithi K, Sarker A, **Wightman RS**, Love J, Calello D, Perrone J. Self-reported tianeptine experiences: a mixed-methods study of reddit users. *Journal of Addiction Medicine*. September/October 2025. 18(5). American Society of Addiction Medicine Annual Conference 2024. Dallas, TX, April 2024.
41. Love J, Perrone J, Lakamana S, Spadaro A, **Wightman RS**, Sarkar A. Themes and descriptions of kratom use in social media data. American College of Medical Toxicology Annual Scientific Meeting 2024. April 2024. Washington DC.
42. Bloom J, Beaudoin FL, Lin T, Wunsch C, Schiavo M, Kaplan S, Gaipo A, **Wightman RS**. Whole-blood cannabinoid and vitamin/mineral profiles in adolescent emergency department patients with cyclic vomiting associated with chronic cannabis use. American College of Medical Toxicology Annual Scientific Meeting 2024. Washington DC, April 2024.
43. **Wightman RS**, Perrone J, Love J, Hariston J, Lakaman S, Sarker A. Characterization of Reddit posts on nitazenes. College on Problems of Drug Dependence 86th Annual Scientific Meeting. Montreal Canada, June 2024.
44. Bloom J, Beaudoin FL, Lin TR, Wunsch C, Gaipo A, Ortega C, **Wightman RS**. Cannabis use patterns and demographics in adolescent emergency department patients with cyclic vomiting associated with chronic cannabis use. College on Problems of Drug Dependence 86th Annual Scientific Meeting. Montreal Canada, June 2024.
45. Badea A, Kapadia SG, **Wightman RS**. Clinical utility of a high-resolution mass spectrometry-based comprehensive drug screen assay in the emergency medicine setting.

22nd International Congress of Therapeutic Drug Monitoring. Banff, Canada, September 2024.

46. Yangchen T, Chambers L, Gaither R, Daly M, Berk J, **Wightman RS**, Beaudoin FL. Barriers and facilitators to accessing overdose prevention, harm Reduction, treatment, recovery and wrap around services related to opioids. American Public Health Association 2024 Annual Meeting. Minneapolis, MN, October 2024.
47. Sompalle P, Sarker A, Love J, Moon J, Spadaro A, **Wightman R**, Perrone J. Deep learning-based detection of xylazine exposure from wound imaging. American Society of Addiction Medicine 2025 Annual Conference. Denver, CO, April 2025.
48. Arthur A, Collins AB, Macon C, Elmaleh R, Pratty C, Dunham K, Levin S, **Wightman RS**. Drug supply monitoring: feedback from people who use drugs. American Society of Addiction Medicine 2025 Annual Conference. Denver, CO, April 2025.
49. Collins AB, Dunham K, Macon C, **Wightman RS**. Informing overdose-related public health efforts in Rhode Island: Using toxicological and qualitative methods to situate drug supply changes in context. APHA 2025. Accepted for oral presentation. Washington, DC, November 2025.

INVITED PRESENTATIONS

International

1. “Precipitated opioid withdrawal from naltrexone injection.” Research presentation. 2016 European Association of Poison Centres and Clinical Toxicologists Annual Congress, Madrid, Spain. May 2016.
2. “Cannabinoid hyperemesis syndrome: clinical trajectories and patterns of use two weeks following a visit to the emergency department for cyclic vomiting.” Invited research presentation- CME. 2023 North American Congress of Clinical Toxicology (NACCT). Montreal, Canada. September 2023.
3. “Using data analytics to guide community responses to the opioid crisis.” Symposium Co-Chair and Panelist- CME. 2024 College on Problems of Drug Dependence 86th Annual Scientific Meeting. Montreal, Canada. June 19, 2024.
4. “Dialed In: Telemedicine Facilitated Buprenorphine Treatment.” Invited speaker- CME. AACT Symposium. 2025 American College of Medical Toxicology Annual Scientific Meeting (ACMT). Vancouver, Canada. April 6th, 2025.

National

1. “Loperamide Overdose.” American College of Medical Toxicology National Case Conference, National Webinar. Virtual. Sept. 2015

2. "Neonatal Lead Poisoning." American College of Medical Toxicology National Case Conference, National Webinar. Virtual. Feb. 2016
3. "Prescription Opioid Harm Reduction Through Erowid.org." Research platform presentation. 2016 Annual Scientific Meeting, American College of Medical Toxicology, Huntington Beach, California. March 2016
4. "Fasoracetam and Phenibut Overdose." American College of Medical Toxicology National Case Conference, National Webinar. Virtual. May 2016
5. "Medication Error Analysis." Discussant. American College of Medical Toxicology National Case Conference, National Webinar. Virtual. July 2016
6. "Clinical Pathologic Case Presentation." Invited discussant. Toxicology for the Emergency Practitioner, NYU School of Medicine, New York, New NY. March 2019
7. "Urine Drug Testing: Interpretation Basics and Pitfalls, Substance Use Screening and Treatment Approach in the ED (SUSTAIN ED)." Lecture- CME. SAHMSA/ACMT National Webinar. Dec. 2019
8. "Opioid Overdose Deaths with Buprenorphine Detected in Post-Mortem Toxicology: A Retrospective Analysis." Research presentation. 2020 Annual Scientific Meeting, American College of Medical Toxicology, New York. March 2020
9. "Linkage to Treatment and Tele-buprenorphine Post-Emergency Department (ED) Opioid Overdose." Research platform presentation. 2020 Symposium on Substance Use Research. Virtual Conference. Nov. 2020
10. "Tele-Buprenorphine During COVID-19: An Opportunity to Improve Access. Innovative Approaches to Mental Health & Substance Use Care in Response to COVID-19." Lecture- CME. Association of Maternal and Child Health Programs. ASTHOCconnects Virtual Webinar. Nov. 2020
11. "Background on Buprenorphine Delivery via Telehealth: A Summary of the Evidence and Regulations." Asynchronous virtual lecture for blended session Lessons Learned from Buprenorphine Telehealth During COVID-19: A Guide for Providers. American Society for Addiction Medicine (ASAM) Virtual due to COVID. March 2021
12. "Lessons Learned from Buprenorphine Telehealth During COVID-19: A Guide for Providers." Speaker, Blended Educational Session Live- CME. American Society for Addiction Medicine (ASAM) Virtual due to COVID. April 2021
13. "Precipitated Withdrawal: When, Where and What to do Next." Speaker, Focus Session- CME. American Society of Addiction Medicine (ASAM) Virtual due to COVID. April 2021

14. "Linkage to Treatment and Tele-buprenorphine Post-Emergency Department (ED) Opioid Overdose." Research platform presentation. American College of Medical Toxicology Annual Scientific Meeting. Virtual due to COVID. April 2021
15. "Low-threshold 24/7 buprenorphine telehealth treatment: innovation to improve access during COVID-19." Short research presentation. American College of Medical Toxicology Annual Scientific Meeting. Virtual due to COVID. April 2021
16. "Precipitated Opioid Withdrawal Management." Invited expert panelist- CME. ACMT and ASAM National Case Conference. National Webinar. June 2021
17. "Toxicological and pharmacologic sex differences in unintentional or undetermined opioid overdose death." Research platform presentation. 2021 Symposium on Substance Use Research. Virtual Conference. Nov. 2021
18. "ED pitfalls: legal concerns in the care of the inebriated patient." Expert panelist- CME. American College of Medical Toxicology 2021 Seminar in Forensic Toxicology. Virtual Conference. Dec 2021
19. "Ethanol case studies and calculations." Presenter and Moderator- CME. American College of Medical Toxicology 2021 Seminar in Forensic Toxicology. Virtual Conference. Dec 2021
20. "Microdosing, macrodosing and XR formulations: Evaluating alternative buprenorphine initiation strategies in the era of high potency opioid analogues and fentanyl." Expert Panelist- CME. American College of Medical Toxicology 2022 Annual Scientific Meeting. Virtual due to COVID19. Mar 2022
21. "Expanding Access to Care through Telehealth: Lessons Learned During the Pandemic." Keynote Speaker Policy and Science Plenary Session- CME. American Society of Addiction Medicine 53rd Annual Conference, Hollywood, FL. Apr 2022
22. "Examining Rhode Island's local drug supply and its impacts on people who use drugs: an introduction to testRI." All-Grantee Meeting, Foundation for Opioid Response Efforts (FORE). Sept 27, 2022
23. "Management options for opioid use disorder." Invited Speaker- CME. American College of Medical Toxicology 2022 Total Tox Course. November 11, 2022
24. "Case Review & Roundtable Discussion on Drug of Addiction." Expert Panelist- CME. American College of Medical Toxicology 2022 Total Tox Course. November 11, 2022
25. "testRI: An update on Rhode Island's local drug supply." Presenter, FORE Data Innovation Grantee Meeting. Virtual, March 27, 2023.

26. “Drug overdose testing (DOT): preliminary service data acceptability and feasibility.” Moderated poster. American College of Medical Toxicology Annual Scientific Meeting. San Diego, CA, April 2, 2023
27. “Wounds, withdrawal, and overdose: what to expect from xylazine drug supply adulteration.” Speaker and panelist- CME. American Society of Addiction Medicine 54th Annual Conference, Washington DC. Apr 14, 2023
28. “Buprenorphine bridges: telehealth solutions to mitigate buprenorphine barriers.” Speaker and panelist- CME. American Society of Addiction Medicine 54th Annual Conference, Washington DC. Apr 14, 2023
29. “Xylazine’s impact on Rhode Island’s Prevention and Strategies.” Invited Speaker. ASTHO CDC Community Learning Webinar, April 20, 2023
30. “State-wide drug testing: xylazine.” Invited speaker and moderator. Managing Patients Taking Xylazine-Adulterated Opioids in Emergency, Hospital, & Addiction Care Settings.” Invited speaker. Clinical Trials Network (CTN) NIDA Webinar. June 14, 2023
31. “Bridging emergency medicine and public health: clinical toxicology laboratory strategies to characterize local drug supplies and drug use patterns.” Speaker and panelist-CME. Association for Diagnostics and Laboratory Medicine, Anaheim CA. July 24, 2023
32. “Drug Overdose Testing (DOT): Future Directions of Xylazine Research.” Invited speaker. Reagan Udall Foundation for the FDA Public Meeting on Xylazine, Washington D.C. October 4, 2023
33. “Advancing Open Science with the HEAL Data Ecosystem.” Invited presenter and panelist- CME. NIH HEAL webinar. November 16, 2023
34. “Overdoses involving xylazine mixed with fentanyl: clinical and public health implications.” Invited expert presenter- CME. Center for Disease Control COCA Call/Webinar. February 29, 2024
35. “Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island.” Speaker- CME. 2024 RX Summit. Atlanta, GA. April 3, 2024
36. “NPS detection and clinical management in the emergency department.” Invited presenter and panelist. 2024 Alliance for Community Drug Checking (ACDC) Learning Summit. Virtual webinar. May 13, 2024
37. “Responding to the threat of xylazine and drug supply adulteration: Clinical testing strategies and empowering point-of-service community discussions.” Speaker- CME. Scientific Session. Association for Diagnostics and Laboratory Medicine 2024. Chicago, IL. July 29, 2024

38. "Toxidromes." Invited Speaker. North American Drug Checking Tech Call, Drug Checking for the People/Remedy Alliance. Virtual. October 18, 2024
39. "Management options for opioid use disorder." Invited speaker- CME. Total Tox Course, American College of Medical Toxicology. Virtual. November 8, 2024
40. "Emerging Illicit Substances: What Clinicians Need to Know." Speaker- CME. American Society of Addiction Medicine 56th Annual Conference, Denver, CO. April 26, 2025
41. "Cannabinoid Hyperemesis Syndrome." Invited Speaker- CME. 2025 Center for Medicinal Cannabis Research (CMCR) Symposium. University of California San Diego. Virtual. October 17, 2025 (planned)

Local/Regional

1. "Verapamil Overdose." Discussant. NYC Consultant's Conference, New York, NY. Oct 2015.
2. "Acetaminophen and Salicylate Toxicity." Lecture. Jacobi Hospital Pediatric EM Fellowship Conference, Bronx, NY. Nov 2015
3. "Precipitated Opioid Withdrawal from IM Naltrexone." Discussant. NYC Consultant's Conference, New York, NY. Dec 2015
4. "Methadone Overdose." Lecture. Dept. of Psychiatry M&M Conference, Bellevue Hospital Center, New York, NY. Dec 2015
5. "Salicylates." Lecture. Intensive Review Course in Clinical Toxicology, NYC Poison Control Center, New York, NY. Mar 2016
6. "Neuromuscular Junction Toxins (Workshop)." Developer and Leader. Intensive Review Course in Medical Toxicology, NYC Poison Control Center, New York, NY. Mar 2016
7. "Caustic Ingestion.:" Dept. of Pediatrics, Bellevue Hospital Center, NYC. Apr 2016
8. "Propranolol OD." Discussant. NYC Consultant's Conference, New York, NY. May 2016
9. "One Pill Killers." Lecture. Jacobi Hospital Pediatric EM Fellowship Conference, Bronx, NY. Nov 2016
10. Guest Lecturer, One Pill Killers, Dept. of Pediatrics, Bellevue Hospital Center, New York, NY. Dec 2016

11. “Dishwasher Detergent Pod Ingestion.” Discussant. NYC Consultant’s Conference, New York, NY. May 2017
12. “Urine Toxicology: Interpretation Pearls and Pitfalls.” Invited presentation- CME. Translating Buprenorphine into Practice, Webinar Alpert Medical School of Brown University, May 2020. <https://cme-learning.brown.edu/content/urine-drug-testing-interpretation-basics-and-pitfalls>.
13. “Urine toxicology testing in the era of fentanyl.” Invited speaker. Project RESPECT. Boston Medical Center. Virtual due to COVID. May 2021
14. “Evidence-Based Treatment of Opioid Use Disorder for RI ED Providers.” Lecture-CME. Webinar, Alpert Medical School of Brown University May 2021. <https://cme-learning.brown.edu/content/evidence-based-emergency-care-opioid-use-disorder#group-tabs-node-course-default1>.
15. “ED Evidence-Based Treatment of Opioid Use Disorder for Nurses.” Lecture-CNE. Webinar, Alpert Medical School of Brown University. May 2021 <https://cme-learning.brown.edu/content/emergency-care-opioid-use-disorder>.
16. “Evidence-Based Emergency Care for Opioid Use Disorder.” Lecture- CME. Kent Emergency Medicine Residency, Dept. of EM. June 2021
17. “Buprenorphine Telehealth: Opportunities and Challenges.” Invited Grand Rounds Speaker- CME. New York University Grossman School of Medicine/New York City Poison Control Center, Virtual due to COVID. Aug 2021
18. “Community, Healthcare, & Policy Innovations.” Panelist at RI COBRE on Opioid and Overdose Hackathon, Providence, RI. Oct 2021
19. “COBRE DRM Core: RIDOH Data Request Process Overview.” Invited Panelist, Providence, RI. May 2022
20. “Audio Only Buprenorphine Telehealth.” Invited Science Talk- CME. 2022 Emerging Areas of Science Rhode Island IDeA Symposium. June 10, 2022
21. “testRI Study Overview.” Invited Presentation at Drug Overdose Surveillance Evaluation (DOSE) Meeting. Rhode Island Department of Health. July 26, 2022
22. “testRI Study Update.” Invited Presentation at Strategic Tangible Overdose Prevention (STOP) Meeting. Rhode Island Department of Health. August 29, 2022
23. “An Introduction to testRI & Emerging Findings from the Local Drug Supply” Invited Presentation at Harm Reduction Working Group Meeting, Governor’s Overdose Taskforce. September 13, 2022

24. “Examining Rhode Island’s local drug supply and its impact on the health of people who use drugs: introduction to testRI and the RI Buprenorphine Hotline.” Invited Presentation at Rhode Island Department of Behavioral Healthcare, Developmental Disabilities & Hospitals (BHDDH) Behavioral Health Provider Meeting. September 19, 2022
25. “testRI: Examining the local drug supply in Rhode Island and its impact on people who use drugs.” Presentation to the Rhode Island Governor’s Overdose Prevention and Intervention Task Force. October 12, 2022. <https://preventoverdoseri.org/wp-content/uploads/2022/10/TF-MasterSlideDeck-Oct2022.pdf>
26. “TestRI: Characterizing xylazine in the local drug supply.” Presentation to the Rhode Island Governor’s Overdose Prevention and Intervention Task Force. March 8, 2023. <https://preventoverdoseri.org/wp-content/uploads/2023/03/TF-MasterSlideDeck-March2023-FINAL.pdf>
27. “Xylazine listening session.” Invited expert. New York City Department of Health Provider Webinar. August 29, 2023
28. “Buprenorphine dosing in the era of fentanyl.” Invited presentation at Drug Overdose Surveillance Evaluation (DOSE) Meeting. Rhode Island Department of Health. October 17, 2023
29. “Levamisole in cocaine.” Invited speaker. Rhode Island Governors Overdose Task Force Harm Reduction Working Group. Webinar. November 15, 2023.
30. “Emerging Issues: Xylazine.” Invited speaker- CME. Annual Substance Exposed Newborns Conference, Rhode Island Department of Health. Cranston, RI. December 12, 2023
31. “Clinical Management of Opioid Use Disorder in Primary Care.” Invited speaker. Primary Care Physician Advisory Meeting Rhode Island. Virtual. January 17, 2024
32. “Fentanyl – Facts & Myths.” Invited speaker for the New York City Department of Health, Manhattan Treatment Court. Virtual February 26, 2024
33. “Buprenorphine Prescribing for Opioid Use Disorder in Primary Care.” Invited presentation- CME. Public Health Out Loud Grand Rounds, Rhode Island Department of Health. Virtual. May 3, 2024
34. “Urine Drug Testing: Interpretation and Pitfalls.” Speaker. New York City Department of Health. Syringe Service Program Buprenorphine Learning Community. Virtual. August 27, 2024
35. “Fentanyl Drug Testing Considerations in Pregnancy.” Invited speaker- CME. Annual Substance Exposed Newborns Conference, Rhode Island Department of Health. Cranston, RI. December 10, 2024

36. “Pregnancy Inpatient Hospital Admission: Needed Pathway Option to Start Medications for Opioid Use Disorder in Pregnancy in Rhode Island.” Speaker. Rhode Island Governor’s Overdose Task Force Meeting. Virtual. January 8, 2025
37. “Alcohol Use in Rhode Island: Data Highlights and Clinical Pearls.” Invited Speaker. Rhode Island Primary Care Physician Advisory Committee. Virtual. March 19, 2025

EDITORIAL POSITIONS

Editorial Board Fellow-in-Training *Journal of Medical Toxicology*
2016 - 2017

Reviewer for peer reviewed journals:

JAMA, JAMA Network Open, Annals of Emergency Medicine, British Medical Journal, Plos One, Addiction, Drug and Alcohol Dependence, British Journal of Clinical Pharmacology, Journal of Addiction Medicine, Clinical Toxicology, Journal of Medical Toxicology, Clinical Therapeutics, American Journal of Emergency Medicine, Substance Abuse

Expert Reviewer Trust for America’s Health *Pain in the Nation*
2024

Assistant Decision Editor, Toxicology *Annals of Emergency Medicine*
2025

GRANTS CURRENTLY HELD

Optimizing methadone treatment strategies for opioid use disorder in the era of fentanyl

NIDA R01DA062186 (MPI Beaudoin, Wightman, Zullo)

Institution: Brown University

Amount: \$4,341,390

9/1/2025- 5/31/2030

Role: MPI

This study will create a unique linked retrospective cohort combining electronic health record and state administrative databases to enable an unprecedented evaluation into exposure and outcomes for methadone treatment across a time of expanded and changing methadone flexibilities in a fentanyl endemic area.

Cannabis use following trauma exposure: an observational study of the impact of acute stress and fear response on cannabis outcomes

NIDA R01DA054116 (MPI Brick, Nugent)

Institution: Brown University

Amount: \$502,995

8/5/2022- 5/31/2027

Role: Co-I

Observational research, informed by evidence that the endocannabinoid system plays an essential role in regulating stress response and learned fear, will examine naturally occurring cannabis use may alter mechanisms contributing to the development of posttraumatic stress symptoms (PTSS).

Identifying optimal buprenorphine dosing for OUD treatment and prevention of overdose
NIDA UH3DA056880 (MPI Beaudoin, Wightman)

Institution: Brown University

Amount: \$1,474,252

12/1/2024- 11/30/2027

Role: MPI

This study evaluates clinical outcomes for patients with a history of fentanyl use seeking MOUD comparing high versus standard buprenorphine maintenance dose.

COMPLETED GRANTS

Prescription Opioid Harm Reduction Through Erowid.org

ACMT/MTF: Prescription Drug Abuse Prevention (Wightman, Nelson)

Institution: New York University School of Medicine

Amount: \$10,000

7/1/2015- 6/30/2016

Role: MPI (Wightman, Nelson)

Project dedicated to prescription opioid harm reduction via survey research and targeted changes to the Erowid drug-use website in order to improve informed decision-making about substance use by website visitors.

Treatment of the Poisoned Patient: Medical Toxicology SIM Curriculum Development

Brown Physicians Inc. Academic Assessment Award 2019 (Wightman)

Institution: Brown Emergency Medicine

Amount: \$12,552

1/2020- 12/31/2020

Role: PI

Goal of project proposal is to create a formalized medical toxicology simulation curriculum for resident physicians and fellows across specialties.

Rhode Island Buprenorphine Hotline

CDC Overdose Data to Action Grant, Subcontract to RI Hospital (Sub-PI Samuels)

Institution: Rhode Island Dept of Health

4/20/2020-8/31/2021

Role: Lead Physician

Seed funding to establish a telephone hotline available 24 hours a day, seven days a week to increase access to buprenorphine for patients with moderate to severe opioid use disorder and provide linkage to continued outpatient treatment.

Unintentional fatal opioid overdose in women: toxicologic and pharmacologic sex differences in cause of death

RI COBRE on Opioids and Overdose Pilot Project (Wightman)

Institution: Rhode Island Hospital

Amount: \$38,154

9/1/2020- 8/31/2021

Role: PI

The goal of this project is to define toxicologic and pharmacologic differences in fatal opioid overdose based on sex via post-mortem toxicology testing analysis of opioid overdose deaths in Rhode Island.

Drug Overdose Testing: A Data Collection and Reporting Emergency

NIGMS 5P20GM12207-04 (Rich), COBRE Center on Opioid and Overdose- Project 6

Institution: Rhode Island Hospital

Amount: \$241,726

9/1/2021- 11/01/2022

Role: Project PI

Evaluation across toxicology testing methods at time of ED overdose for evaluation of substance exposure including NPS and active cut.

CTN0099 ED-INNOVATION

NIDA UGI DAO015831 (D'Onofrio)

Institution: NIDA/Yale University; The National

Drug Abuse Treatment Clinical Trials Network

6/1/2020-5/31/2022; 01/01/2023- 08/01/2023

Roles: Site PI, Site Co-I

Randomized control trial comparing sublingual buprenorphine to investigational injection extended-release buprenorphine formulation.

Cannabis Hyperemesis Syndrome: An Increasing Challenge in Emergency Care

NIDA R21DA055023 (Wightman)

Institution: Rhode Island Hospital

Amount: \$646,126

7/1/2021-12/1/2023 (NCE 6/2024)

Role: PI

Mixed method study evaluating cannabis use in relation to symptoms and disease progression and explore motivations and barriers to change cannabis use and treatment engagement in patients with CHS.

Cannabis Hyperemesis in Adolescents: An Increasing Challenge in Emergency Care

Brown Physicians Inc. Academic Assessment Grant 2021(Wightman)

Institution: Brown Emergency Medicine

Amount: \$50,000

10/2021- 12/31/2023

Role: PI

Goal of this study is to characterize the relationship between cyclic vomiting and cannabis use in adolescents and evaluate biological cannabinoid toxicology profiles.

Drug Checking Pilot Evaluation: Massachusetts Drug Supply Datastream (MADDS)

Massachusetts Dept of Health/SAMHSA (Green)

Institution: Brandeis University

3/1/2020- 6/30/2023

Role: Sub-contractor

This study uses handheld FTIR testing with GC-MS confirmation to analyze drug samples from community sites and provide safety information to community partners and track emerging drug use trends.

**RI Department of Behavioral Health, Developmental Disabilities Access Grant/
Buprenorphine Hotline**

RI Department of BHDDH / SAHMSA (Samuels, Clark)

Institution: Rhode Island Hospital

9/1/2020- 5/31/2024

Role: Physician Lead

Project lead on SAMHSA-funded COVID emergency response project to establish and run a 24/7 Buprenorphine Telehealth Hotline for the state of Rhode Island.

Identifying optimal buprenorphine dosing for OUD treatment and prevention of overdose

NIDA UG3DA056880 (MPI Beaudoin, Wightman)

Institution: Brown University

Amount: \$424,978

7/01/2022- 6/30/2024 (NCE)

Role: MPI

This study evaluates clinical outcomes for patients with a history of fentanyl use seeking MOUD comparing high versus standard buprenorphine maintenance dose.

Understanding Drug Use Within a Rapidly Changing Supply: An Ethnographic and Toxicologic Investigation to Improve Overdose Prevention and Supply Surveillance Communication

Foundation for Opioid Response Efforts (FORE) (MPI Wightman, Collins)

Institution: Brown University

Amount \$564,391

2/15/2022-2/14/2024 (NCE 8/31/24)

Role: MPI

An integration of ethnographic, epidemiologic, and toxicologic methods to track the evolving opioid crisis at the street level to form prevention and response approaches.

Implementing statewide emergency department care pathways for addiction recovery after opioid overdose

CDC ROI CE19001 (MPI Beaudoin, Baird)

Institution: Rhode Island Hospital

9/1/2019-8/31/2024 (NCE)

Role: Physician

The goals of this study are to: (1) refine and test an implementation strategy that aims to improve the fidelity of ED post-overdose care as it relates to the state's Levels of Care policy, and (2) to test the effectiveness of policy-driven ED-based post-overdose care.

GRANTS REVIEWER

Reviewer ACMT/MTF Innovative Grant Competition
2020- 2022

Reviewer CDC Grant Review Panel
May 4-5, 2022
Special Emphasis Panel NOFO-CE22-011: Understanding Polydrug Use Risk and Protective Factors, Patterns, and Trajectories to Prevent Drug Overdose

Reviewer NIDA/NIH Grant Review Panel
June 21 and 23, 2022
RFA-DA-22-50: HEAL Data2Action Research Adoption Support Center
RFA-DA-22-051: HEAL Data2Action Innovation Projects
RFA-DA-22-049: HEAL Data2Action Modeling and Economic Resource Center
RFA-DA-22-052: HEAL Data2Action (HD2A) Data Infrastructure Support Center

Reviewer NIDA/NIH Grant Review Panel
March 22, 2023
RFA-DA-22-051: HEAL Data2Action – Innovation and Acceleration Projects, Phased Awards

Reviewer NIDA/NIH Grant Review Panel
August 2, 2023
PAR-20-20:0 Development of Medications to Prevent and treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3)

Reviewer NIDA/NIH Grant Review Panel
May 22, 2024
RFA-DA-24-066: HEAL Data2Action Implementation Substance Use Preventive Services (R66;R33)

Reviewer NIDA/NIH Grant Review Panel
May 1 and 7, 2025
RFA-DA-23-053, NIH HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)

Guest Member Summer 2025 NIH Lifestyle and Health Behaviors Study Section
June 11,12, 2025
Population Sciences and Epidemiology Integrated Review Group

UNIVERSITY TEACHING ROLES

Teaching Facilitator, Autonomic Nervous System (Workshop), Medical Student Pharmacology Course, New York University School of Medicine Nov 2015 (100 students).

Lecturer, Acetaminophen Toxicity, NYU Medical Student Toxicology Selective, New York University School of Medicine Dec 2015 (8 students).

Lecturer, Introduction to Medical Toxicology, Emergency Medicine Medical Student Elective, New York University School of Medicine Feb 2016 (20 students).

Leader, Management of the Agitated Patient Simulation, Medical Student Interclerkship Intensive, New York University School of Medicine Sep 2016 (60 students).

Leader, Clinical Pharmacology (Workshop), Medical Student Pharmacology Course, New York University School of Medicine Oct 2016 (40 students).

Leader, Autonomic Nervous System Simulation (Workshop), Medical Student Pharmacology Course, New York University School of Medicine Nov 2016 (40 students).

Lecturer, Management Acetaminophen Poisoning, NYU Medical Student Toxicology Selective, New York University SOM Jan 2017 (7 students).

Lecturer, Approach to Poisoned Patient, Emergency Medicine Medical Student Elective, New York University SOM Jan 2017 (20 students).

Leader, Chest Pain Assessment Simulation, Transitions to Residency Program, New York University School of Medicine May 2017 (20 students).

Lecturer, Intro to Pharmacology: Drug Development and Safety, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Nov 2018 (144 students).

Guest Lecturer, Emerging Patterns of Drug Abuse: Novel Opioids, PHP1520- Emergency Medical Systems: An Anatomy of Critical Performance, Undergrad School of Public Health at Brown University Mar 2019 (50 students).

2nd Year Doctoring **Faculty Community Mentor**, Niralee Shah '22, Alpert Medical School of Brown University (4 hrs/wk, 13 wks, 1 student/yr) 2019-2020.

Invited Judge, 12th Annual Warren Alpert Medical School Academic Symposium, Alpert Medical School, Brown University. Nov 13, 2019

Lecturer, Intro to Pharmacology I: Drug Development and Safety, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Dec 2, 2019 (144 students).

Lecturer, Intro to Pharmacology IV: Drug Dosing, Webinar, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Dec 10, 2019 (144 students).

Leader and Developer, Pharmacokinetics Problem Set and Workshop, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Dec 12, 2019 (144 students).

Lecturer, Mushrooms, BIOL 6652- Wilderness Medicine, Alpert Medical School of Brown University Apr 13, 2020 (10 students).

Faculty, Sex and Gender Emergency Medicine Medical Student Elective, Alpert Medical School of Brown University Sept 2020- 2022 (10 students/year). Precept medical students on clinical shift and provide dedicated teaching in sex/gender pharmacology.

Lecturer, Scientific Foundations of Medicine: Pharm I, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Nov 30, 2020 (144 students), remote due to COVID.

Lecturer, Scientific Foundations of Medicine: Pharm IV, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Dec 11, 2020 (144 students), remote due to COVID.

Developer and Leader, Scientific Foundations of Medicine: Pharmacokinetics Workshop, 1st Year Medical Student Pharmacology Course, Alpert Medical School of Brown University Dec 11, 2020 (144 students), remote due to COVID.

Lecturer, Mushrooms, EM 5660- Wilderness and Environmental Medicine, Alpert Medical School of Brown University Apr 8, 2021 (10 students).

Lecturer, Substance Use Treatment Research: Perspectives and Practicality, Addiction Medicine Interest Group, Alpert Medical School of Brown University Nov 21, 2024 (10 students).

GRADUATE MEDICAL EDUCATION

Instructor, ACLS/PALS, NYU Dept EM. 2011- 2015

Facilitator, Journal Club, NYU Dept of EM. 2013-2014

Facilitator, Morning Report Resident Educational Conference, NYU Dept of EM. 2014- 2015

Facilitator, Journal Club, New York City Poison Control Center. 2015- 2017

Lecturer and Facilitator, Visiting Medical Student and Resident Toxicology Rotation, New York City Poison Control Center. 2016- 2017

Supervisor and Teacher, Emergency Medicine Resident Clinical Education, New York University School of Medicine/Bellevue Hospital Center. 2015-2017

Supervisor and Teacher, Emergency Medicine Resident Clinical Education, Alpert Medical School of Brown University/Brown University Health. 2017-present

- Precept 1-2 emergency medicine residents, off service residents, and/or medical students per clinical shift.

Core Content Developer and Lecturer, Medical Toxicology Rotation, Emergency Medicine Residency Training Program, Alpert Medical School of Brown University.

- 20 lectures per year, 13 resident rotators and 1-2 addiction medicine fellows per year. 2017-2020

Director of Toxicology Education, Medical Toxicology Rotation, Emergency Medicine Residency Training Program, Alpert Medical School of Brown University.

- Develop and lead curriculum for toxicology education for emergency medicine residents including asynchronous online education, conference presentations, and simulation teaching and workshops. 2020-2023

Director of Toxicology and Addiction Medicine, Division of Medical Toxicology, Department of Emergency Medicine, Alpert Medical School of Brown University

- Direct the Division of Medical Toxicology and Addiction Medicine, oversee clinical, educational, and research initiatives related to toxicology and addiction medicine. 2023- current

DEPARTMENTAL LECTURES

1. **Lecturer**, “Vaginal Bleeding in Pregnancy.” EMS Lecture Series, NYU Medical Center, March 2012.
2. **Lecturer**, “Acute Life-Threatening Event.” NYU Dept. of EM Residency Conference, Nov. 2012.
3. **Developer and Leader**, “Asthma/Copd Workshop.” Intern Report, NYU Dept. of EM, July 2013.
4. **Presenter**, “Tarlov Cyst.” Interdepartmental Monthly Case Presentation, NYU Dept. of EM, Sept. 2013.
5. **Teaching Facilitator**, “Splinting Workshop.” Intern Report, NYU Dept. of EM, Feb 2014.
6. **Lecturer**, “Pelvic Trauma.” EM/Surgery Joint Conference, NYU Dept. of EM Residency Conference, Feb. 2014.
7. **Developer and Leader**, “Medication Dosing Safety (Workshop).” Intern Report, NYU Dept. of EM, May 2014.

8. **Lecturer**, “Sexually Transmitted Infection Updates.” NYU Dept of EM Residency Conference, May 2014
9. **Presenter**, “Tide Pod Ingestion.” Interdepartmental Monthly Case Presentation, NYU Dept. of EM, June 2014.
10. **Lecturer**, “Diagnostic Imaging for Nephrolithiasis.” EM Journal Update, NYU Dept. of EM Residency Conference, July 2014.
11. **Lecturer**, “Pediatric Head Trauma.” EM Journal Update, NYU Dept. of EM, Oct. 2014.
12. **Lecturer**, “Morbidity, Mortality, and Improvement.” NYU Dept. of EM Residency Conference, June 2015.
13. **Leader**, “Gastric Lavage (Workshop).” Resident Conference, NYU Dept. of EM, April 2016.
14. **Leader**, “Salicylate Overdose (Workshop).” Resident Simulation, NYU Dept. of EM, April 2016.
15. **Leader**, “Acid/Base (Workshop).” Resident Conference, NYU Dept. of EM, July 2016.
16. **Leader**, “Calcium Channel Blocker Overdose Workshop.” Resident Simulation, NYU Dept. of EM, April 2017.
17. **Lecturer**, “Cyanide Poisoning.” Resident Conference, NYU Dept. of EM, April 2017.
18. **Leader**, “Toxic ECGs (Workshop).” Resident Conference, NYU Dept. of EM, April 2017.
19. **Lecturer**, “Cyanide Poisoning.” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Nov. 2017.
20. **Leader and Developer**, “Salicylate Toxicity (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2018.
21. **Leader and Developer**, “Anticholinergic Poisoning (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Feb. 2018.
22. **Toxicology Content Advisor**, “Non-Cardiogenic Pulmonary Edema Precipitated Opioid Withdrawal (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Nov. 2018.
23. **Leader and Developer**, “Calcium Channel Blocker Overdose (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Dec. 2018.

24. **Lecturer**, “Caustic Ingestions: Updates in Management.” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2019.
25. **Leader and Developer**, “GI Decontamination Workshop.” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2019.
26. **Leader and Developer**, “Iron Ingestion (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Feb. 2019.
27. **Toxicology Content Advisor**, “Organophosphate Disaster (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School, May 2019.
28. **Lecturer**, “Chemical Warfare and Bioterrorism.” EMS Fellowship Brown Emergency Medicine, Alpert Medical School of Brown University, May 2019.
29. **Leader and Developer**, “Pediatric GI Decontamination Workshop.” Pediatric EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, Oct. 2019.
30. **Leader and Developer**, “Pediatric Salicylate Toxicity (Simulation).” Pediatric EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, Oct. 2019.
31. **Leader and Developer**, “Methylxanthine Overdose (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2020.
32. **Lecturer**, “Chemical Warfare and Bioterrorism.” Emergency Medical Systems Division, Brown Emergency Medicine, Alpert Medical School of Brown University, May 2020.
33. **Faculty Leader**, “Toxicology Journal Club. Buprenorphine to Reverse Respiratory Depression from Methadone.” Brown Emergency Medicine Residency, Dept. of EM, Alpert Medical School of Brown University, June 2020.
34. **Lecturer**, “Evidence-based Emergency Care for Opioid Use Disorder.” Brown Emergency Medicine Residency, Dept. of EM, Alpert Medical School of Brown University, Nov. 2020.
35. **Leader and Developer**, “Clonidine Pediatric Overdose (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2021.
36. **Leader and Developer**, “Loperamide Toxicity (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, Jan. 2021.
37. **Leader and Developer**, “Clonidine Pediatric Overdose (Simulation).” Pediatric EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, Feb. 2021.

38. **Leader and Developer**, “Hydrofluoric Acid Exposure (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, March 2021.
39. **Leader and Developer**, “INH ingestion (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, September 2021.
40. **Leader and Developer**, “Status Epilepticus: Pediatric INH Ingestion (Simulation).” Pediatric EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, Oct. 2021.
41. **Leader and Developer**, “Hydrocarbon exposure (Simulation).” Pediatric EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, February 2023.
42. **Leader and Developer**, “Pediatric hydrocarbon exposure (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, February 2023.
43. **Leader and Developer**, “Gastrointestinal decontamination workshop.” PEM EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, March 2024.
44. **Leader**, “Pediatric anticholinergic syndrome (Simulation).” PEM EM Fellow Conference, Dept. of EM, Alpert Medical School of Brown University, March 2024.
45. **Leader**, “Anticholinergic syndrome (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, October 2024.
46. **Facilitator**, “Methadone ED Pathway Introduction Brown EM.” Resident Conference, Dept. of EM, Alpert Medical School of Brown University, October 2024.
47. **Lecturer**, “Rhode Island Drug Supply.” Addiction Medicine Fellow Conference, Dept. of Psychiatry, Alpert Medical School of Brown University, September 2025.

UNIVERSITY ADVISING AND MENTORING ROLES

Group Leader, “How to Engage Effectively with a Mentor,” Women in Medicine Mentoring Night Program, Alpert Medical School of Brown University, Oct 26, 2017. (5 students).

Mentor, Jonathan Fletcher, MD, PGY2 Dept of EM, Alpert Medical School of Brown University, 2017- 2018.

Fletcher JM, Hack JB, **Wightman RS**. Digoxin recrudescence: a life-threatening reality for end stage renal disease patients. J Med Tox. 2018;14(1):33. American College of Medical Toxicology Annual Scientific Meeting. Washington DC, April 2018.

Mentor, Shihab Ali, MD, PGY2 Dept of EM, Alpert Medical School of Brown University, Aug. 2018.

Ali S, **Wightman RS**, Hack J. Acute Respiratory Failure from Cement Exposure: A Case Report and Review of the Literature. *Rhode Island Medical Journal*. February 2019:55-57

Group Leader, “Women in Academic Medicine and Leadership,” Women in Medicine Mentoring Night Program, Alpert Medical School of Brown University, Oct. 11, 2018. (30 students).

Research Mentor, Clayton Stehr, Undergrad Brown University, 2018- 2019.

Wightman RS, Stehr C. Can the FDA’s Adverse Event Reporting System (FAERS) Data Be Used to Assess the Impact of Interventions Such As Risk Evaluation and Mitigation Strategies (REMS)? *Clin Tox*. 2019;57(10):931. North American Congress of Clinical Toxicology Nashville, TN, Sept 25 2019.

Faculty Advisor, Chicago Medical School, North Chicago, Illinois, 2018- 2019.

Advisees: Christopher Gideon M1; Oliver Drewry M2.

Mentor, Matthew Leon, BS, Brown Emergency Medicine Medical Scribe Program, 2018- 2019.

Career counseling for medical school application process.

Class 2023 F. Edward Hebert School of Medicine at the Uniformed Services University, Washington DC.

Mentor, Josh Kaine, MD, PGY2 Dept of EM, Alpert Medical School of Brown University, Mar 7, 2019.

“Toxic Rainbow.” Ignite Presentation. RIACEP. Providence, RI.

Research Mentor, Victoria Zeyl Class of ’2022, Alpert Medical School of Brown University, 2019-2020.

Zeyl T, Sawyer K, **Wightman RS**. What do you know about Mary Jane? Literature review on the THC: CBD Ratio. Submitted for presentation American College of Medical Toxicology 2020. Annual Scientific Meeting, New York, NY.

Mentor, Travis Hase, MD, PGY4 Dept of EM, Alpert Medical School of Brown University, 2019.

Acetaminophen Overdose. EMRA Pressor dex 4.0.

Group Leader, “Career Paths in Medicine,” Women in Medicine Mentoring Night Program, Alpert Medical School of Brown University, Oct. 1, 2019. (10 students).

Group Leader, “Women in Medicine Specialty Night,” Office of Women in Medicine and Science, Alpert Medical School of Brown University, Jan. 30, 2020.

Research Mentor, Caroline Meehan, MD PGY2 Dept of EM, Alpert Medical School of Brown University, Apr. 2020.

Meehan C, **Wightman RS**. A Case Report of Isopropanol Ingestion During the SARS-CoV-2 Pandemic. *J Addict Med*. Sept/Oct 2020;14(5):e264-266. DOI: 10.1097/ADM.0000000000000728.

Mentor, Sean Reid, MD PGY2 Dept of EM, Alpert Medical School of Brown University, 2020-2023.

Hydrofluoric acid exposure (Simulation).” Resident Conference, Dept. of EM, Alpert Medical School of Brown University.

Sean R, **Wightman RS**. Cannabinoid Hyperemesis Syndrome. Systematically Testing the Evidence on Marijuana (STEM). Collaborative project between the US Department of Veterans Affairs and the Center for Evidence-based Policy at Oregon Health & Science University. February 2023. <https://www.cannabisevidence.org/clinician-resources/clinician-briefs/cannabinoid-hyperemesis-syndrome/>

Group Leader, “Women in Medicine Specialty Night,” Virtual Zoom Event due to COVID19. Office of Women in Medicine and Science, Alpert Medical School of Brown University, Jan 26, 2021.

Research Mentor, Katherine Stewart, MD PGY2 Dept of EM, Alpert Medical School of Brown University, Sept. 2021- current.

Stewart K, Francis V, **Wightman RS**. Statewide variation in cannabinoid regulations. *Rhode Island Medical Journal*. March 1, 2023;106(2):31-33. PMID:3684540.

Research Mentor, Kyle Volpe, MD PGY2 Dept of EM, Alpert Medical School of Brown University, Jul 2022- 2024.

Volpe K, Wightman RS. Delta what? Deciphering the world of cannabinoids. *Rhode Island Medical Journal*. September 1, 2022;105(7):37-41. PMID:36041020.

Research Mentor, Sonia Kapadia, MS1, Alpert Medical School of Brown University, Nov 2022- June 2026. Thesis Mentor, Master of Science Population Medicine, Alpert Medical School of Brown University.

Kapadia S, **Wightman RS**, Beaudoin FL, Park C, Krieger MS, Tokarz S, Badea A. Which should you order? Blood vs. urine toxicology LC-QTOF-MS testing. American Society of Addiction Medicine Annual Conference 2024. April 6th, 2024. Dallas, TX.

Awardee, Department of Pathology, Lifespan “Best Poster Presentation.”

Research Mentor, Frankie Pappalardo, MS2, Alpert Medical School of Brown University, Nov 2022- 2024. Research Mentor.

Pappalardo F, Krieger M, Park C, Beaudoin F, **Wightman RS**. Naloxone practices and overdose history among patients presenting to the emergency department with non-fatal drug overdose. *Clinical Toxicology*;61(2):A101. North American Congress of Clinical Toxicology (NACCT). September 2023. Montreal, Canada.

Research Mentor, Jeffrey Savarino, MD PGY3, Brown Emergency Medicine, 2023. Research Mentor.

Savarino J, Mokszycki R, Tubbs R, Wightman RS. Refractory hypoglycemia due to sulfonylurea contamination of illicit opioid medication. *Clinical Toxicology*; 61:A351. North American Congress of Clinical Toxicology (NACCT). September 2023. Montreal, Canada.

Research Mentor, Amy Arthur, MS1, Alpert Medical School of Brown University, January 2024- current. Mentor for PLME Summer Research Assistantship in Emergency Medicine Fellowship Awardee.

Arthur A, Collins AB, Macon C, Elmaleh R, Pratty C, Dunham K, Levin S, Wightman RS. Drug supply monitoring: feedback from people who use drugs. *American Society of Addiction Medicine 2025 Annual Conference*. April 25, Denver, CO.

Winner Abstract Submission Honorable Mention Award ASAM

Research Mentor, Jhanavi Kapadia, MS1, UNE College of Osteopathic Medicine, February 2024- current. Mentor for Research Fellowship Award from UNE College of Osteopathic Medicine.

Kapadia J, Wightman RS. Evaluating the Feasibility and Acceptability of a Novel Biological Drug-Checking Model in Emergency Departments: A Pilot Study. *UNE COM Research and Scholarship Fall Forum*. Nov. 1, 2024. Portland, ME.

References Available Upon Request